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and Practicalities for the N-ALIVE Randomized Trial
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ABSTRACT The naloxone investigation (N-ALIVE) randomized trial commenced in the
UK in May 2012, with the preliminary phase involving 5,600 prisoners on release. The
trial is investigating whether heroin overdose deaths post-prison release can be
prevented by prior provision of a take-home emergency supply of naloxone. Heroin
contributes disproportionately to drug deaths through opiate-induced respiratory
depression. Take-home emergency naloxone is a novel preventive measure for which
there have been encouraging preliminary reports from community schemes. Overdoses
are usually witnessed, and drug users themselves and also family members are a vast
intervention workforce who are willing to intervene, but whose responses are currently
often inefficient or wrong. Approximately 10% of provided emergency naloxone is
thought to be used in subsequent emergency resuscitation but, as yet, there have been no
definitive studies. The period following release from prison is a time of extraordinarily
high mortality, with heroin overdose deaths increased more than sevenfold in the first
fortnight after release. Of prisoners with a previous history of heroin injecting who are
released from prison, 1 in 200 will die of a heroin overdose within the first 4 weeks.
There are major scientific and logistical challenges to assessing the impact of take-home
naloxone. Even in recently released prisoners, heroin overdose death is a relatively rare
event: hence, large numbers of prisoners need to enter the trial to assess whether take-
home naloxone significantly reduces the overdose death rate. The commencement of
pilot phase of the N-ALIVE trial is a significant step forward, with prisoners being
randomly assigned either to treatment-as-usual or to treatment-as-usual plus a supply of
take-home emergency naloxone. The subsequent full N-ALIVE trial (contingent on a
successful pilot) will involve 56,000 prisoners on release, and will give a definitive
conclusion on lives saved in real-world application. Advocates call for implementation,
while naysayers raise concerns. The issue does not need more public debate; it needs
good science.
BACKGROUND
The pilot phase of the naloxone investigation (N-ALIVE) trial is funded by the Medical
Research Council in the UK and is investigating the extent to which deaths from heroin
overdose in the ﬁrst 12 weeks post-release from prison can be prevented by prior provision
of a take-home emergency supply of naloxone. The N-ALIVE trial is the largest-ever
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planned randomized intervention trial with a prisoner sample (or, to bemore precise, at the
point of release), and involves 5,600 prisoners on release in the initial pilot randomized
phase, then extending to its randomized sample size of 56,000 for the full N-ALIVE trial.
The full N-ALIVE trial protocol will be published separately as a trial protocol
publication (in preparation, April 2013). In this publication, we present the
background scientiﬁc, clinical and political rationale, and considerations of
objective, partners, interventions and measures—all crucial before the trial design
and protocol can even be considered meaningfully. How have the decisions about
the medication itself and the associated intervention, the study population, the
period of study and the outcome measures been made?
A Novel Intervention
Take-home emergency naloxone has been proposed as a novel preventive measure to
reduce the likelihood of a fatal outcome from heroin overdose amongst drug
users.1–21 However, in the wider community context, reports of pilot naloxone-
prescribing schemes10,14,15,19,21–25 have mostly comprised anecdotal reports of
small-scale interventions with systematic follow-up rarely included, and the true
nature and extent of beneﬁt remain uncertain.
Implementation of take-home naloxone has been recommended in the UK by the
Advisory Council on the Misuse of Drugs (ACMD)26 which recognized the potential
contribution that take-home naloxone could make and expressed the opinion that
‘as a matter of principle, naloxone should be made more widely available’
accompanied by attention to implementation issues. A more recent report from
ACMD27 further recommended government ‘… to consider naloxone’s role in steps
to make an impact on drug-related death rates’. However no large-scale study of
actual effectiveness has yet been conducted.
This is a clear instance of where the interactive relationship between science and
policy should move center stage,28 with policy asking a question of science, and with
science giving a clear guiding reply.
THE NEED FOR STRONGER RESEARCH AND THE ORIGINS
OF THE N-ALIVE TRIAL
The origins of the N-ALIVE trial were as a result of conﬂuence of the drive to develop
more effective methods to prevent the striking excess mortality of heroin users (excess
even compared with users of other illicit drugs such as cocaine),1,2,5–7,12, 15 alongside
the recent scientiﬁc study and recognition of the extraordinary concentration of deaths
in the weeks immediately following release from prison misuse.8,29–34
We considered three particular aspects: ﬁrstly, the special importance of heroin;
secondly, prison as a remarkable concentration of heroin users; and thirdly, the
particular concentration in time and context of heroin overdose deaths.
Drug Deaths—the Special Importance of Heroin
(and the Opiates)
Heroin and the opiates contribute disproportionately to drug deaths: even though
heroin comprises a minority part of the total use of illicit drugs in the UK, it nevertheless
contributes more than 80 % of all drug overdose deaths.26,35 Opiates are thus heavily
implicated in the attention to deaths as one of the major harms of illicit drug
misuse.36–42 Many of these opiate overdose deaths also involve simultaneous use of
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other types of drugs (e.g. benzodiazepines and/or alcohol);13, 24,36,43–46 nevertheless, it
is the respiratory depression caused by opiates that is the main mechanism of death.47
Concentrations of Heroin Users—Special Concentration
in Prisons
Prisons have an intense, but also complicated, relationship with the heroin-using behavior of
so many of their inmates and represent an often overlooked potential intervention
opportunity, notwithstanding their primary criminal justice function.48–50 While this varies
across societies (according to different criminal justice responses to the drugmisuse problem),
prisons nevertheless comprise an extraordinary concentrationof the population at risk of later
heroin overdose death. Society achieves, by onemeans or another, an intense concentrationof
heroin misusers in its prison population: in the UK, the population lifetime prevalence of less
than 1% amongst the general public is transformed into approximately 40% in the prison
population, both in sentenced populations8,51–55 and also in remand populations 56–59 and
has particularly high levels amongst female prisoners.60–62 Furthermore, prison can actually
be the setting in which heroin use can be initiated.63,64 Earlier work by our group identiﬁed
not only the high pre-incarceration rates of heroin use (at 32 % amongst men) but also the
considerable extent to which there was continued use of opiates while still imprisoned50,52
—and hence the high probability of re-establishment of heroin use on eventual release.
Concentration of Heroin Overdose Deaths on Release
from Prison
The period following release from prison is a time of extraordinarily high
mortality, with heroin overdose deaths concentrated in the ﬁrst few weeks
following release8,29–31,33, 34—a period identiﬁed as a ‘reliable, brief window period of
extremely high risk’ during which we observe ‘carnage among recently released
prisoners’.32 Several studies have now demonstrated this phenomenon in different
countries, with risk of overdose death increased more than sevenfold in the ﬁrst
fortnight after release (and remaining signiﬁcantly elevated in the second fortnight)
before gradually subsiding back to heroin users’ baseline (but still high) mortality
rate.8,29–31,33 Of prisoners with a previous history of heroin injecting who are
released from prison, an estimated 1 in 200 will die of a heroin overdose within
the ﬁrst 4 weeks of release. Directly comparable ﬁgures are hard to ﬁnd, but this
is approximately 10 times the mortality rate of general prisoners being released
(who themselves have an increased risk) and approximately 100 times greater than
an age-matched general population.
Concentrations of Individuals with Risk Behavior
and Concentrations of Deaths in Speciﬁc Time:
the Special Importance of Prison
Prisons are thus important for two different reasons. Firstly, society achieves, by one
means or another, an extraordinary concentration of heroin users in its prison
population. The second particular importance of prison is that the period following
release from prison is a time of extraordinarily high mortality, with heroin overdose
deaths concentrated in the ﬁrst few weeks following release.
Considering the Potential for Adverse Reactions
Concerns about potential unforeseen consequences have been expressed65,66 which
include the following: that the resuscitation advice may not be heeded or may be
applied incorrectly; that there may be possible adverse reactions to naloxone; that
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the resuscitated overdose victim may subsequently drift back into overdose; that
blood-borne virus transmission could result from inadvertent needle-stick injury or
from re-use. We see these concerns as falling into two major categories that warrant
careful attention.
Firstly, the planned intervention may fail to be applied—either not applied at all, or
applied insufﬁciently. There is the possibility that however well-intentioned, the
circumstances of the overdose may be such that no one present is appropriately
knowledgeable or sufﬁciently capable to apply the emergency naloxone (and wider
resuscitation) intervention. There is also the possibility that there may be technical or
operator failure of the naloxone administration. For these reasons, amongst others, we
provide the emergency naloxone dose in a pre-ﬁlled syringe, in which there is more than
adequate dose (0.8 mg to be given from a pre-ﬁlled syringe actually containing 2 mg
naloxone), with instructions for it to be given by the much simpler intramuscular route
(in contrast to the often intravenous administration by accident and emergency doctors
and ambulance paramedics). The pre-ﬁlled syringe is given to the N-ALIVE participant
in a special general purpose N-ALIVE wallet which not only functions as a regular
wallet but also contains essential N-ALIVE information and also the needle and syringe
(to be assembled) with the emergency naloxone dose. In the design of the N-ALIVE
research study, we have additionally incorporated a post-release telephone interview
with a sub-sample (random 50 % of those who consent to telephone follow-up within
the ﬁrst month), and also questionnaire-based re-interview of all N-ALIVE participants
who are re-incarcerated to allow us to gather more descriptive information about any
overdose events that may have occurred and the emergency use (or loss) of the pre-
provided naloxone.
A second category of concern is that the very provision of the resuscitation ability
may, paradoxically, increase the risk of overdose by virtue of the perception of a
‘safety net’, provided by the naloxone, which might create a lowered perception of
the real risk of fatality and thereby encourage more risky behavior. At least some
evidence indicating that this risk may be real can be seen in the response from
injecting drug users themselves—amongst whom 6 % indicated, when interviewed
about the potential appropriateness of pre-provision of take-home naloxone, that
they believed that the provision of such rescue medication may indeed lead them to
use more heroin 2. Prisoners in Barlinnie prison, Glasgow, with whom we discussed
this possibility answered frankly that they did not know how they would react.
A third, different type of concern, is that the approach may also be regarded as
politically risky, since it could mistakenly be seen to be condoning drug use.
The theoretical possibility of adverse reactions is not sufﬁcient grounds to stand in
the way of a randomized effectiveness study if the a priori plausible beneﬁt signiﬁcantly
exceeds the potential harm. The real risk of sudden death needs to be borne in mind
while paying proper attention to any evidence that may emerge of adverse effects.
FEASIBILITY OF PROPOSED INTERVENTION
In the consideration of the N-ALIVE trial, it was necessary for there to be reasonable
evidence of the operational feasibility of the proposed intervention—not only that
the prescribed emergency supply of opiate anti-dote naloxone would be sufﬁcient to
reverse heroin overdose but also that the deliverers of the proposed intervention
deliverers (peers and/or family) would not only be likely to be present but also
would be willing to be the workforce who deployed the novel intervention.
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The Willingness of Users or Family Members to Intervene
Thosewho inject heroin are at high risk of overdose themselves11,43,46, 67–69 but they are
also highly likely to witness the overdose of others—with more than three quarters of
injecting heroin users having witnessed an overdose.4,9, 16,43,67,70–73 They are thus
potentially a vast intervention workforce who are willing to intervene,3,18,69,74 but whose
actions are currently often inefﬁcient or wrong11,16,73,75,76 andwho consequently need to
be properly trained and provided with the appropriate tools. Furthermore, a quarter of
parents at family support groups have already witnessed the overdose of a son or
daughter.6 In short, a large and well-aware intervention workforce exists.
The extensive willingness of these groups to be actively involved in emergency
resuscitation, including the administration of a naloxone injection (if necessary) has
now been documented, not only amongst drug users in treatment but also
particularly importantly amongst those not currently in treatment2,4,9,18 and also
amongst carers (e.g. family members).6 Indeed, there is clear evidence of active
intervention at previous witnessed overdoses, even when the interventions have been
the wrong interventions.4,11,16,73,76 For example Beswick et al. 76 found evidence of
probably ineffective and potentially harmful interventions, such as additional
injection of other drugs (e.g. cocaine), injection of salt, immersion in cold bath,
and administering ice. Despite the extent of ﬂawed knowledge, the important
conclusion is with regard to the evident strong commitment to intervene
amongst fellow injecting drug users and also family members6 that can be
addressed by training.
To recap, not only has a large potential intervention workforce been identiﬁed but
also a reported high level of commitment to be taught how to intervene actively. From
mostly small-scale pilot naloxone provision schemes, the proportion of distributed
naloxone that is used in life-saving interventions is estimated by active clinical teams to
be 10 %.15,22 But, as yet, there have been no deﬁnitive randomized trials, with
appropriate study design, to establish the extent of beneﬁt (or possible harm) accrued.
And it is this scientiﬁc evidence vacuum that the N-ALIVE trial addresses.
Naloxone Delivery
It is likely that the emergency naloxone will need to be administered either by a peer
drug user or by a family member, and hence practical decisions were necessary
about the most appropriate recommended route of administration, the right dose,
and the wider resuscitation management.
Intramuscular injection is an efﬁcient and easily-implemented route of naloxone
administration and would appear well-suited to this context. In recent community-
based overdose training for drug users10,14,15,19,21,77 and for carers,6 the
recommended route of administration is intramuscular as this is more suitable for
non-specialist administration. Furthermore, even when administered by ambulance
personnel, the greater speed with which an intramuscular or subcutaneous injection
can be given means that the delay from arrival until recovery of the overdose victim
is practically the same as with intravenous administration.78
The right dose of naloxone to be provided proved difﬁcult to decide. On the one hand,
0.4mg is sometimes sufﬁcient, but not always—and the next step would be a repeat dose
(i.e. an additional 0.4 mg a few minutes later, thus a total of 0.8 mg), and, if still no
response, a further 0.8 mg. Furthermore, in the clinical algorithms used by accident and
emergency departments, these dose schedules relate to intravenous administration, and
the provision of naloxone by the intramuscular route has a pathway directly to the
0.8-mg initial dose.79 Consequently, in the N-ALIVE trial, we provide a pre-prepared
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emergency supply of a single dose of 0.8 mg, which is the recommended intramuscular
dose in various ambulance and Emergency Medicine protocols in the UK and accords
with the clinical algorithm in the Emergency Medical Journal.79 Extra doses can then
later be given by the emergency medical personnel and/or ambulance staff who
subsequently attend the overdose victim.
A possible and simpler means of pre-providing a 0.8-mg naloxone emergency
dose might have been by provision of two 0.4-mg doses (which existed already
as commercial formulations), and this solution might be appropriate in
community treatment settings, or in a purely observational study. However, in
the N-ALIVE trial, this option was not acceptable because of the increased risk
of contamination between the experimental and control groups with, for
example, ‘gift’ of one of the naloxone 0.4-mg syringes (from a N-ALIVE participant
randomized to the ‘naloxone-on-release’ intervention) to a fellow release randomized to
‘treatment-as-usual’.
Concern has been raised about the relatively short duration of action of
naloxone (in the region of an hour or two of main antagonist effect), and the
possible drift back into life-threatening overdose (as the naloxone wears off),
but this would seem largely ill-founded on the basis of the absence of any
deaths recorded over the 5-year study period in San Diego of 998 heroin users
who, post-naloxone resuscitation, discharged themselves against medical advice:
perhaps some degree of intoxication did occur, but none of these individuals
died in the subsequent 12-h period.80,81 If it transpired that the relatively
shorter duration of action of naloxone (versus heroin, and certainly versus some
prescribed pharmaceutical opiates such as methadone) was a valid cause for
concern, then either repeat doses may need to be provided (as sometimes
provided to recovered overdose victims by ambulance personnel) or alterna-
tively a longer-acting opiate antagonist such as nalmefene could be considered
instead. However, given the 40-year history and extensive experience of use of
naloxone for reversal of heroin overdose, the N-ALIVE trial is using standard
pharmaceutical naloxone.
Naloxone can only save life if it is accessible at the time and place of overdose
emergency. Recent surveys of the target population of drug users in treatment
suggest that the traditionally provided naloxone is probably only carried ‘on the
person’ by about 20 % of subjects.77 We consequently provide an N-ALIVE wallet
to each N-ALIVE naloxone participant, in which there is a pouch which contains the
naloxone-loaded syringe. For the N-ALIVE trial, information and video demonstra-
tion is available on the MRC website at www.ctu.mrc.ac.uk/research_areas/
study_details.aspx?s080. We also give each N-ALIVE participant a DVD instruc-
tional video on essential resuscitation steps and naloxone administration, and the
t r a i n i ng i s a l s o ava i l ab l e on YouTube a t www.you tube . com /
watch?v0Xbnx5Q3vZek in order to explain the N-ALIVE trial itself and also at
www.youtube.com/watch?v0eMkEndVJi7w&feature0relmfu to provide instruction
on the basics of overdose management and also on potential emergency adminis-
tration of an injection of naloxone.
DESIGN OF THE N-ALIVE TRIAL
Many scientiﬁc and logistical challenges have been encountered and have needed to
be resolved in the design and introduction of the N-ALIVE trial so as to be able to
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quantify the effectiveness (or otherwise) of pre-provision of take-home emergency
naloxone and the extent of impact on reducing overdose deaths.
Selection of Randomized Over Observational Trial
Design:
An early crucial decision was whether a randomized trial design (versus observa-
tional trial design) was feasible; and, if feasible, whether it was ethical. We consider
these two aspects in this section.
The wider provision of pre-placed supply of emergency naloxone has been
proposed over more than a decade (ﬁrst seriously articulated in 19961) and yet is
still the subject of questions about the likelihood of expected genuine beneﬁt, as well
as intervention inertia. In such circumstances, and with continued expressions of
uncertainty or doubt, the clarity of conclusions from a suitably well-designed and
objectively undertaken randomized trial would be a powerful inﬂuence on key
decision-makers, just as in other contentious domains.28,82 However, it is only
possible to plan and deliver a randomized trial with participation and consent from
the relevant service providers and also crucially from the study population
themselves. We have consequently worked closely with the agencies responsible for
provision of healthcare in the prison environment (which itself was moved in recent
years into the central NHS83) to ensure their partnership and support, and we also
explored the viability of the proposed trial design with prisoners and ex-prisoners
themselves. The high rate of prisoner transfers mitigated against a cluster
randomized trial design (including stepped-wedge84,85) with prison as unit of
randomization, and we also wished to incorporate individually informed prisoner
consent to randomisation. Consequently, mindful of the continued public and
political uncertainty of true effectiveness of naloxone-on-release, and seeking the
strongest appropriate trial design for a deﬁnitive implementation trial, we proceeded
with the opportunity to conduct a full-scale deﬁnitive randomized trial.
Ethical issues were also prominent in our consideration, with acute awareness that
we might well be providing a life-saving intervention to one group while withholding it
from another. In addition to consideration of clinical equipoise, we also needed to
consider whether there was policy equipoise. At the time of conducting the study,
naloxone is not provided to prisoners on release in England (apart from one prison for
women where it had been introduced for a while by an ‘early adopter’). Consequently,
at all other prisons, there was no withholding from any prisoner on release of any
existing treatment or intervention. All prisoners received full offers of participation in
education about risk of overdose and, if provided within the particular prison, training
in emergency resuscitation. Similarly, no constraints were placed on provision (or non-
provision) of treatments such as methadone or buprenorphine maintenance, or
naltrexone—these are all generally approved treatments in the UK, although not
always provided as frequently to those with heroin addiction problems within the
prison population as would typically be provided in the community context. However,
for the trial design, we merely needed to record these other interventions at the time of
randomization (by minimization, which takes account of them).
The pre-provision of emergency naloxone remains a contentious proposal in some
quarters, and indeed the N-ALIVE trial received challenge on the grounds (mistaken,
and misleading) that it involved giving an experimental injectable drug to detoxiﬁed
prisoners. In fact, the ‘experimental’ intervention (the pre-provision of a take-home
supply of emergency naloxone) involves the provision of a medication developed more
than 40 years ago, and being prescribed in an approved form (for intramuscular
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injection) and for the speciﬁc purpose for which it is clinically indicated (reversal of
opiate overdose): the only novel aspect of the provision was the innovative proposal of
pre-placement of the antidote injection with the individual at risk, accompanied by
training materials for peers, family and friends via YouTube.
It had originally been planned to conduct the N-ALIVE trial across the UK, but
the decision by Fergus Ewing, Scotland’s Minister for Community Safety and Legal
Affairs, to introduce Scotland-wide provision of naloxone to community and prison
release populations at risk of overdose necessitated restriction of the N-ALIVE trial
to England (population 52.2 million) since the window of opportunity with policy
equipoise had now closed in Scotland (population 5.2 million) (we explore this
different development in Scotland in a separate publication—Bird et al., submitted).
Additionally, in May 2011, Wales (population 3.0 million) also adopted take-home
naloxone as a public health policy.
Selecting the Right Study Sample
The study sample of current or former heroin injectors on release from a period of
imprisonment has been chosen speciﬁcally because of their identiﬁed excess risk of
overdose death. However, even amongst this population, death is a relatively rare event
(1 in 200 in ﬁrst 4 weeks post-release), and hence large numbers of eligible prisoner-
participants need to be randomized to demonstrate as statistically signiﬁcant a plausible
30 % reduction in overdose deaths. It is scientiﬁcally efﬁcient to consider populations in
which the event is particularly likely to occur, and at times in their drug-using careerwhen
the event may be at increased frequency. Hence, mindful of the marked concentration of
overdose deaths in the weeks immediately following release from prison, 8,29–31 the N-
ALIVE trial of take-home emergency naloxone has taken, as its study population,
prisoners with a history of heroin injection who are being released from prison.
Using data from the Ofﬁce of National Statistics (which catalogues every death in the
UK), we are then subsequently cross-checking our study sample’s identities and release
dates against all deaths (in the relevant age-group) in order to identify participants’ deaths
(and cause of death) in the 12 weeks following release. Comparison of the death rates
amongst prisoners randomized to standard health information and after-care versus
those randomized to the provision of a take-home emergency supply of naloxone in
addition to standard after-care is thus the primary outcomemeasure of beneﬁt conferred.
The Problem of the Changing Therapeutic Landscape
There is a shifting baseline in the extent and potential beneﬁts from approved
evidence-based treatments,86 and also in the recognized importance of healthcare
provision in the prison context.87 Some of these changes will undoubtedly occur
over the course of the N-ALIVE trial, such as improvements in through-care from
prison to community (especially continuity of opiate substitution treatment), and the
possible introduction of more widespread methadone or buprenorphine mainte-
nance programs as has been commenced in the UK and as has been implemented in
other countries.88–91 However, the extent of shift of baseline is variable and
unpredictable.92 Randomization ensures that these changes are affecting equally the
two comparison groups in the N-ALIVE trial, and we record changes in these
practices while evaluating the extent of beneﬁt from take-home emergency
naloxone. Beneﬁt from naloxone may be reduced by more effective continuity of
treatment, or the beneﬁt may remain just as pronounced if the overdose deaths are
more closely causally related to deliberate post-release excess, rather than just
resulting from lack of knowledge about loss of tolerance. Baseline data from
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Scotland (2007–2009) support the latter hypothesis since maintenance treatment in
recent years has been readily available and yet 79/547 (14.4 %) of all Scotland’s
male opiate-related deaths under the age of 35 still occurred within 4 weeks of
prison release, much as in 1996-1999.8
The N-ALIVE Trial Starts
The ﬁrst subject was recruited into the N-ALIVE randomized trial in May 2012, and
trial participants are now being released from prison after having been randomized
to either pre-provision of an emergency dose of naloxone (plus information etc.), or
alternatively to information but without naloxone supply. This is a signiﬁcant step
forward in the construction of a robust evidence based on how effectively take-home
emergency naloxone and training in overdose resuscitation can reduce the extent of
overdose deaths in this population.
During this initial pilot phase of the trial, 5,600 prisoners are being randomly
assigned to either pre-provision of take-home emergency naloxone, accompanied by
explanatory leaﬂets and instruction for themselves, peers and families, or
alternatively to a protocol-driven treatment-as-usual (thus with literature warning
of the risk of post-release overdose). Through the full N-ALIVE trial, a total of
56,000 released prisoners will have to be randomized.
This sample size has been calculated on the basis of detecting a 30 %
reduction—from the anticipated 140 deaths during the ﬁrst 4 weeks of release amongst
the control group of 28,000 eligible ex-prisoners down to a lower level of just under 100
deaths. N-ALIVE’s power calculation is based on various evidence-informed assump-
tions. If naloxone were universally available, with a competent other always present
who had sufﬁcient competence to administer the naloxone, and if properly administered
(while also calling ambulance and placing victim in the recovery position, and
maintaining assisted breathing etc.), then a survival rate of close to 100 % would
presumably be expected for this highly effective opiate anti-dote. However, we are
assuming a much more modest penetration of the study population at risk. Since our
interest is in real-life application, the preparation for the N-ALIVE trial, and the
underlying power calculations, have taken cognizance of the likely real-life application
of instructions and hence arrive at a more modest prior estimation of effectiveness. We
calculate as follows: we know that as summarized above, approximately 80 % of
overdoses occur in the presence of others, and we have conservatively assumed that
during the ﬁrst 4 weeks after release, 75 % of victims will still have their supply of
naloxone; we have then assumed that there is perhaps only a 50:50 chance that the
other person present will locate the naloxone and have the competence, courage and
conﬁdence to administer the intramuscular naloxone. With these assumptions, we thus
calculate a 30 % probability of naloxone administration (50 % of 75 % of 80 %0
30%), and, when combinedwith our knowledge of data onmortality rates in the weeks
following prison release (summarized above), we identify a necessary sample size of
56,000 (28,000 across each of the two conditions). For fuller details of the power
calculation, and also of processes and procedures, the reader is directed to our
forthcoming paper on the N-ALIVE trial protocol (in preparation, April 2013).
CONCLUSION: DRUG-RELATED DEATHS, MISSED
OPPORTUNITIES AND THE APPLIANCE OF SCIENCE
The start of the N-ALIVE trial is a highly signiﬁcant scientiﬁc step in the development of
an evidence-based harm reduction initiative to stem the hemorrhage of heroin overdose
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deaths that has been identiﬁed as occurring in the period immediately post-prison release.
The results from the N-ALIVE trial will also have profound importance for the planning
and provision of more effective responses sight across the addiction treatment ﬁeld, and
particularly with regard to the community prevention of the marked excess mortality of
heroin users after other high-risk discharges, such as from hospital.93 The N-ALIVE trial
stands as an examplar research study selected and designed to give a deﬁnitive answer to
society at large, politicians and policymakers, as well as to clinicians and researchers,
with results likely to have wide generalizable signiﬁcance.
Advocates call for action, while naysayers raise concerns. N-ALIVE will test this
speciﬁc proposed method of reducing the overdose death carnage post-prison
release; it will give us a robust evidence base on which to make important decisions;
and it will increase our understanding of the interacting relationships between drug-
taking behavior and associated health hazards, the application of criminal justice
sanctions, and the provision of health interventions. Wider provision of naloxone
has now been proposed (and opposed) for more than a decade. The issue does not
need more public debate; it now needs good science.
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